What is PTCT's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 5.40B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for PTCT?

P/E (TTM) is n/a and 52-week range is $61.23 to $90.87 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s PTCT figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for PTCT?

The company profile lists revenue (TTM) near $909M, net income (TTM) near $-3.46B, EPS (TTM) near $-0.59 when available from the market-data feed. Figures are informational and may lag live markets.

Where is PTC Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Warren, New Jersey, US, 83M shares outstanding, ISIN US69366J2006 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

PTC Therapeutics Inc

$PTCT

Health Care · Biotechnology

IR Run Scenarios

$64.70

+3.42%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company is headquartered in Warren, New Jersey and currently employs 991 full-time employees. The company went IPO on 2013-06-20. The firm is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).

Employees

991

Website

www.ptcbio.com/

IPO

2013-06-20

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)